Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GR1802 in moderate to severe atopic dermatitis
NCT06216392Phase 3Not yet recruiting
- Sponsor
- Zhixiang Jintai
- Start
- Jan 2024
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of telikibart in atopic dermatitis (AD), sponsored by Zhixiang Jintai. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
telikibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06216392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06216392.